Table. Baseline Characteristics of the Overall Safety Population.
| Characteristic | Placebo (n = 222) | Daily atogepant dose | Total (N = 902) | ||
|---|---|---|---|---|---|
| 10 mg (n = 221) | 30 mg (n = 228) | 60 mg (n = 231) | |||
| Age, mean (SD), y | 40.3 (12.8) | 41.4 (12.1) | 42.1 (11.7) | 42.5 (12.4) | 41.6 (12.3) |
| Sex, No. (%) | |||||
| Female | 198 (89.2) | 200 (90.5) | 204 (89.5) | 199 (86.1) | 801 (88.8) |
| Male | 24 (10.8) | 21 (9.5) | 24 (10.5) | 32 (13.9) | 101 (11.2) |
| Race, No. (%) | |||||
| African American/Black | 24 (10.8) | 34 (15.4) | 38 (16.7) | 28 (12.1) | 124 (13.7) |
| Alaska Native or American Indian | 0 | 1 (0.5) | 1 (0.4) | 1 (0.4) | 3 (0.3) |
| Asian | 2 (0.9) | 2 (0.9) | 1 (0.4) | 7 (3.0) | 12 (1.3) |
| White | 194 (87.4) | 181 (81.9) | 185 (81.1) | 192 (83.1) | 752 (83.4) |
| Missing | 0 | 0 | 0 | 1 (0.4) | 1 (0.1) |
| Multiplea | 2 (0.9) | 3 (1.4) | 3 (1.3) | 2 (0.9) | 10 (1.1) |
| Ethnicity, No. (%) | |||||
| Hispanic | 23 (10.4) | 21 (9.5) | 19 (8.3) | 14 (6.1) | 77 (8.5) |
| Non-Hispanic | 199 (89.6) | 200 (90.5) | 209 (91.7) | 217 (93.9) | 825 (91.5) |
| BMI, mean (SD) | 30.8 (8.7) | 30.4 (7.6) | 31.2 (7.6) | 29.9 (7.3) | 30.6 (7.8) |
| MMDs, mean (SD), No.b | 7.5 (2.4) [214] | 7.5 (2.5) [214] | 7.9 (2.3) [223] | 7.8 (2.3) [222] | 7.6 (2.4) [873] |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); MMD, monthly migraine-day.
Participants who reported multiple races are only included in the multiple category.
Migraine-day is defined as any day meeting criteria A, B, and C or D and E: A, headache with at least 2 of the following characteristics: unilateral location, pulsating quality, moderate to severe pain, and/or aggravated by or causing avoidance of routine physical activity; B, at least 1 of the following: nausea and/or vomiting, photophobia and phonophobia, and/or typical aura accompanying or within 60 minutes of headache; C, headache lasting at least 2 hours unless an acute, migraine-specific medication was used; D, headache fulfilling 1 criterion from A and at least 1 criteria from B or at least 2 from A and no criteria from B; and E, headache lasting at least 2 hours unless an acute, migraine-specific medication was used.